

pINFUSE-hIgG4-Fc1

Plasmid designed for the construction of Fc-Fusion proteins

Catalog # pfc1-hgin4

For research use only

Version # 08C12-SV

PRODUCT INFORMATION

Content:

- 20 µg of pINFUSE-hIgG4-Fc1 plasmid provided as lyophilized DNA.
- 4 pouches of *E. coli* Fast-Media® Zeo (2 TB and 2 Agar)

Storage and Stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C and is stable 3 months.
- Resuspended DNA should be stored at -20°C and is stable up to 1 year.
- Store *E. coli* Fast-Media® Zeo at room temperature. Fast-Media® pouches are stable 18 months when stored properly.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pINFUSE-Fc is a family of plasmid developed to facilitate the construction of Fc-fusion proteins by fusing the effector region of a protein to the Fc region of an immunoglobulin G (IgG). pINFUSE-Fc plasmids yield high levels of Fc-fusion proteins. The level of expression is usually in the µg/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, CHO cells, monkey COS cells and human embryonic kidney (HEK)293 cells, cells that are commonly used in protein purification systems.

pINFUSE-Fc plasmids allow the secretion of Fc-Fusion proteins. As Fc-Fusion proteins are secreted, they can be easily detected in the supernatant of pINFUSE-Fc-transfected cells by SDS-PAGE. Furthermore, functional domains can be identified by immunoblotting and ligand blotting.

Fc-Fusion proteins can be easily purified by single-step protein A or protein G affinity chromatography.

InivoGen provides pINFUSE-Fc vectors featuring Fc regions containing introns from different species and isotypes. In humans, there are four isotypes: IgG1, IgG2, IgG3 and IgG4. The Fc region mediates effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). IgG isoforms exert different levels of effector functions increasing in the order of IgG4<IgG2<IgG1≤IgG3.

PLASMID FEATURES

- **human genomic IgG2-Fc (with introns):** The Fc region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the two parts of the Fc-fusion protein, allowing each part of the molecule to function independently. A short intron is present between each region (one intron between the hinge and CH2 and one intron between CH2 and CH3). The presence of introns is known to enhance the level of gene expression as splicing is known to promote rapid and efficient mRNA export¹. Human IgG4 displays low ADCC and CDC.
- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter² and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat³. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **MCS:** The multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA⁴.
- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **CMV enh / hFerL prom:** This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin™-resistance gene in mammalian cells.
- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.
- **Zeo:** Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptomyces hindustanus*. The same resistance gene confers selection in both mammalian cells and *E. coli*.
- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁵.

TECHNICAL SUPPORT

Toll free (US): 888-457-5873

Outside US: (+1) 858-457-5873

Europe: +33 562-71-69-39

E-mail: info@invivogen.com

Website: www.invivogen.com

METHODS

Plasmid resuspension:

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20°C.

Selection of bacteria with *E. coli* Fast-Media®

Fast-Media® is a **fast and convenient** way to prepare liquid and solid media for bacterial culture by using only a microwave. Fast-Media® is a TB (liquid) or LB (solid) based medium that already contains the antibiotic. Fast-Media® Zeo is available separately: #fas-zn-l (liquid), #fas-zn-s (agar).

- 1- Pour the contents of a Fast-Media® pouch into a clean borosilicate glass bottle or flask.
- 2- Add 200 ml of distilled water to the flask
- 3- Heat in a microwave on MEDIUM power setting (about 400Watts), until bubbles start appearing (approximately 3 minutes). **Do not heat a closed container. Do not autoclave Fast-Media®.**
- 4- Swirl gently to mix the preparation. **Be careful, the bottle and media are hot, use heatproof pads or gloves and care when handling.**
- 5- Reheat the media for 30 seconds and gently swirl again. Repeat as necessary to completely dissolve the powder into solution. But be careful to avoid overboiling and volume loss.
- 6- Let agar medium cool to 45°C before pouring plates. Let liquid media cool to 37°C before seeding bacteria.

Note: Do not reheat solidified Fast-Media® as the antibiotic will be permanently destroyed by the procedure.

References:

1. Nott A, et al. 2003. A quantitative analysis of intron effects on mammalian gene expression. RNA. 9(5):607-17.
2. Kim DW et al. 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23.
3. Takebe Y, et al. 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72.
4. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58.
5. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.

RELATED PRODUCTS

Product	Catalog Code
Zeocin™	ant-zn-1
Fast-Media® Zeo TB	fas-zn-l
Fast-Media® Zeo Agar	fas-zn-s

TECHNICAL SUPPORT


Toll free (US): 888-457-5873

Outside US: (+1) 858-457-5873

Europe: +33 562-71-69-39

E-mail: info@invivogen.com

Website: www.invivogen.com



PvuI (11)
SgfI (11)
 1 **GGATCCTCGATCCTCCGGTCCCCGTAGTGGCAGAGGCCACATGCCAACAGTCCCCGAGAAGTTGGGGGAGGGTCGCAATTGAACGGTGCTA**
 101 **GAGAAGGTGGCGGGGTAAACTGGAAAGTGTGATGTCGTACTGGCTCCGCTTTTCCGAGGGTGGGGAGAACGTATAAGTCAGTAGTCGCC**
HindIII (246)

Psp1406I (205)
PvuII (242)
 201 **GTGAACTTCTTTGCAACGGTTGCGCCAGAACACAGCTGAAGCTCGAGGGCTCGCATCTCTCCTCACGC**
 301 **GCCATCCACGCCGGTTGAGTCGCTCTGCCCTCCGCTGTGGCCTCTGA**
 401 **GGCCCTTGTCCGGCCTCCCTGGAGCCTACCTAGACTCAGCCGGCTCCACGCTGACCCCTGCTCAACTTACGTCTTGTGCTT**
Bs36I (293)

EcoRI (559) **XbaI (570)**
KasI (536) **AgeI (553)** **EcoRV (567)** **BglIII (586)**
 501 **TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCCCTACCTGAGATCACCGGTGAATTGATATCTGAGCACCATGGTTAGATCTCCCCCATGC**
1▶ ProProCys

601 CCATCATGCCAGtaagccaaccaggcctcgccctcagctaaggcggacagggtccctagacttagcctgcattccaggacaggccccagccgggt
4▶ ProSer CysPro

701 gctgacgcattccacacctccatcttttcctcagCACCTGAGTTCTGGGGGACCATCAGTCTTCTGTTCCCCCAAACCCAAGGACACTCTCATGATCT
1▶ ProGl uPheLeuGl yGl yProSer Val PheLeuPheProProLysProLysAspThr LeuMet l leS

PmlI (819)
Eco72I (819)
BbrPI (819)
Bs36I (810)

801 CCCGGACCCCTGAGGTACGTGCGTGGTGGGACGTGAGCCAGGAAGACCCGAGGGTCCAGTTCACTGGTACGTGGATGGCGTGGAGGTGCATAATGC
23▶ erArgThr ProGl uVal Thr CysVal Val Val AspVal Ser Gl nGl uAspProGl uVal Gl nPheAsnTrpTyrValAspGl yVal Gl uVal Hi sAsnAl

901 CAAGACAAAGCCGGGGAGGAGCAGTTAACAGCACGTACCGTGTGGTACCGTCTCACCCTGACCCAGGACTGGCTAACCGCAAGGAGTACAAG
56▶ aLysThr LysProArgGl uGl uGl nPheAsnSer Thr TyrArgVal Val Ser Val LeuThr Val LeuHi sGl nAspTrpLeuAsnGl yLysGl uTyrLys

DraIII (1075)
SandI (1063) **PshAI (1091)**
1001 TGCAAGGTCTCAAACAAAGGCCCTCCGTCCATCGAGAAAACCATCTCAAAGCCAAAGGtggaccccacggggtgcgagggccacatgacacagaggt
90▶ CysLysVal Ser AsnLysGl yLeuProSer Ser l leGl uLysThr l leSer LysAl aLys

1101 cagctcgcccccacccctctgcccggggagtgaccgctgtgccaaacctctgtccctacagGGCAGCCCCGAGAGCCACAGGTGACACCTGCCCCCATCCC
1▶ Gl nProArgGl uProGl nVal TyrThr LeuProProSer G

1201 AGGAGGAGATGACCAAGAACCAAGGTCAGCCTGACCTGCTGGTCAAAGGCTTCTACCCAGCGACATGCCGTGGAGTGGAGAGCAATGGCAGCCGA
14▶ l nGl uGl uMetThr LysAsnGl nVal Ser LeuThr CysLeuVal LysGl yPheTyrProSerAsp l leAl aVal Gl uTrpGl uSerAsnGl yGl nProGl

XmnI (1396)
1301 GAACAACTACAAGACCACGCCCTCCGTGCTGGACTCCGACGGCTCCTCTTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGAAAT
47▶ uAsnAsnTyrLysThr Thr ProProVal LeuAspSerAspGl ySer PhePheLeuTyrSer ArgLeuThr Val AspLysSer ArgTrpGl nGl uGl yAsn

Ppu10I (1418)
NsiI (1423)
MscI (1492)
BaiI (1492)
NheI (1484)

1401 GTCTTCTCATGCTCCGTATGCAATGAGGCTCTGCACAACCACTACACAGAACGCTCTCCCTGCTCCGGTAATGAGTGCTAGCTGCCAGACAT
81▶ Val PheSer CysSer Val MetHi sGl uAl aLeuHi sAsnHi sTyrThr Gl nLysSer LeuSer LeuSer ProGl yLys***

1501 GATAAGATAATTGATGAGTTGGACAAACCAACTAGAACATGCACTGAAAAAAATGCTTATTGTGAAATTGTGATGCTATTGTTATTGTAACC

HpaI (1624)
1601 ATTATAAGCTGCAATAAACAAAGTTAACACAACAAATTGCAATTCTATTATGTTTCAAGGTTCAAGGGGAGGTGGAGGTTAAAGCAAGTAAAC

VspI (1721)
AseI (1721)
XmnI (1717)

1701 TCTACAAATGTGGATGGAATTAAATTCTAAACACAGCATAGCAAACCTTAACCTCAAATCAAGCCTACTTGAATCCTTCTGAGGGATGAATAA
→ ←

1801 GGCATAGGCATAGGGCTGGCCAATGTGCATTAGCTGTTGCAGCCTACCTCTTCTACAGGTTAAAGATATAGTGTATTCCCAGGTTGAA

SspI (1963) **SwaI (1978)**
1901 CTAGCTCTCATTCTTATGTTAAATGCACTGACCTCCCACATCCCTTTAGTAAATATTCAAATACATCATTGCAATGAAA

2001 TAAATGTTTTATTAGGCAGAACATCCAGATGCTCAAGGCCCTCATAATATCCCCAGTTAGTGGACTAGGAACAAAGGAACCTTAATAGAA

ApaLI (2160)
DraIII (2159) **EagI (2174)**
2101 ATTGGACAGCAAGAAAGCGAGCTTAGCTTACCTCAGTCTGCTCTGCCACAAAGTCAGCAGGTCAGTTGCCGGCGGGTCGCGCAGGGCAACTCCC
125▶ ***AspGl nGl uGl uAl aVal PheHi sVal CysAsnGl yAl aProAspArgLeuAl aPheGl uAr

2201 GCCCCCACGGCTGCTGCCGATCTCGTCATGGCGCCGGAGGCGCTCCCGGAAGTTCGTGGACACGACCTCCGACACTGGCGTACAGCTCGTCCAG
103▶ gGl yTrpProGl nGl uGl y l leGl uThr MetAl aProGl ySer Al aAspArgPheAsnThr Ser Val Val Gl uSer TrpGl uAl aTyrLeuGl uAspLeu

SgrAI (2391)
2301 GCCGCGACCCACACCCAGGCCAGGGTGTGTCGGCACACCTGGCTCTGGACCGCGCTGATGAACAGGGTCAGCTCGTCCGGACACACCGGGCAAG
70▶ Gl yArgVal TrpVal TrpAl aLeuThr AsnAspProVal Val Gl nAspGl nVal Al aSer l lePheLeuThr Val AspAspArgVal Val Gl yAl aPheA

XmaI (2417)
SmaI (2419)
BsrBI (2458)
BssHII (2469)

2401 TCGTCCTCACGAAGTCCCAGGAGAACCCGAGCCGGTCCAGAACCTGACCGCTCCGGCGACGTGCGCGCGTGGAGCACCGAACGGCACTGGTCA
36▶ spAspGl uVal PheAspArgSer PheGl yLeuArgAspThr TrpPheGl uVal Al aGl yAl aVal AspArgAl aThr LeuVal ProVal Al aSer Thr Le

MscI (2506)
BaiI (2506)

2501 ACTTGGCCATGATGGCTCTCtgcaggagaggaaagagaaggtagtacaattgCTATAGTGAGTTGATTACTATGCAGATATACTATGCCA
3▶ uLysAl aMet

VspI (2605)
 AseI (2605) PstI (2627)
 2601 **ATGATTAATTGTCAAACTAGGGCTGC**Agggttcatagtgccactttcctgactgccccatctcccccaccctttccaggcatagacagtca
 HindIII (2731) SacII (2749)
 2701 **cttac**CAAACTCACAGGAGGGAGAAGGCAGAAGCCTGAGACAGACCCGGGACCGCCGA
 ←
 BspEI (2888)
 2801 CGCGGCCCTCGAGGCAGGGCGCTGGGAGGCCTAGCGGCCAATCTCGGTGGCAGGAGGCGGGCGAAGGCCGTGCCTGACCAATCCGAGCACAT
 SpeI (2996)
 Bsp120I (2988)
 2901 AGGAGTCTCAGCCCCCGCCCCAAAGCAAGGGGAAGTCACGCCCTGTAGGCCAGCGTGTGAAATGGGGCTTGGGGGGTTGGGGCCCTGACTAG
 3001 TCAAAACAAACTCCCATTGACGTCAATGGGTGGAGACTTGGAAATCCCCGTAGTCAAACCGCTATCCACGCCATTGATGACTGCCAAAACCGCATC
 ←
 SnaBI (3126)
 Eco105I (3126)
 3101 ATCATGGTAATAGCGATGACTAACAGTAGATGTACTGCCAAGTAGGAAAGTCCATAAGGTATGTACTGGCATAATGCCAGGCAGGCCATTACCGT
 NdeI (3230)
 3201 CATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGCAGTTACCGTAATAACTCCACCCATTGACGTCAATGGAA
 3301 AGTCCCTATTGGCGTTACTATGGAACATACGTATTGACGTCAATGGCGGGGTCGGCGGTAGCCAGGCAGGCCATTACCGTAAGTT
 PacI (3419)
 PstI (3412)
 SdaI (3412) BspLU11I (3425)
 3401 GTAACGCCCTGCAGGTTAATTAAGAACATGTGAGCAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAGGCCGCTTGTGGCTTTCCATAGGCTCCG
 3501 CCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCAAACCCGACAGGACTATAAGATAACCAGGCCTTCCCCCTGAAAGCTCCCTC
 3601 GTGCGCTCTCTGTTCCGACCCCTGCCCTACCGATACTGTCCGCCCTTCTCCCTGGAAAGCGTGGCGTTCTCATAGTCACGCTGTAGGTATC
 ApaLI (3739)
 3701 TCAGTTGGTGTAGGTGTTGCTCCAAGCTGGCTGTGTCAGCAACCCCCCTTCAGCCGACCGCTGCCCTATCCGTAACATCGTCTTGAGTC
 3801 CAACCCGTAAGACACGACTTATGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCCTGCTACAGAGTTCTGAAGTGG
 3901 TGGCTTAACTACGGCTACACTAGAACAGTATTGGTATCTGCCTGCTGAAGCCAGTTACCTCGGAAAAAGAGTTGGTAGCTCTGATCCGGCA
 4001 AACAAACCACCGCTGGTAGCGGTGGTTTTGTTGCAAGCAGCAGATTACGCCAGAAAAAAGGATCTCAAGAACATCCTTGATTTCTACGGG
 EagI (4175)
 PacI (4159) SwaI (4167) NotI (4175)
 4101 GTCTGACGCTCAGTGGAACGAAACTCACGTTAAGGGATTTGGTATGGCTAGTTAATTAACATTAAATCAGCGCCGCAATAAAATATCTTATTT
 4201 CATTACATCTGTGTTGGTTTTGTTGTAATCGTAACATACGCTCTCCATCAAAACAAACGAAACAAACAAACTAGCAAATAGGCTGCCC
 4301 CAGTGAAGTGCAGGTGCCAGAACATTCTCTATCGAA